Vasoptic Medical

Executive Summary

Vasoptic Medical is a privately held medical device company based in Rochester, NY, pioneering non-invasive imaging solutions for real-time blood flow monitoring. Its core technology, Laser Speckle Contrast Imaging (LSCI), enables video-rate visualization of pulsatile blood flow without the need for contrast agents, addressing a critical need in diagnosing ocular and microvascular diseases. Founded in 2014, the company targets both clinical diagnostics and research applications, positioning itself in the cardiovascular, medical devices, and diagnostics sectors. With a focus on safe, contrast-agent-free imaging, Vasoptic aims to improve early detection and management of conditions such as diabetic retinopathy, macular degeneration, and peripheral vascular disease. The company has developed proprietary devices that provide quantitative hemodynamic data, offering potential advantages over traditional imaging modalities like fluorescein angiography. While Vasoptic Medical's specific stage and funding details are undisclosed, its technology has garnered interest from the ophthalmology and vascular research communities. Upcoming catalysts include potential FDA 510(k) clearance for its retinal imaging system, strategic partnerships with hospital networks or device distributors, and publication of clinical validation data. Given the rising prevalence of microvascular diseases and the demand for point-of-care diagnostics, Vasoptic Medical represents a compelling investment opportunity in the non-invasive imaging space.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Retinal Blood Flow Imager60% success
• Q4 2026Strategic Partnership or Distribution Agreement50% success
• Q2 2026Publication of Key Clinical Study Results80% success